Connect with us

Cannabis

Ministry of Public Health Argentina Received the First Delivery of CBD Oil for Epilepsy Patients

The Ministry of Public Health will be in charge of the distribution, while Biofactory Misiones and Misiopharma work together in the production process. They explained that the product made between the Biofactory and MisioPharma -MISCBD-, in addition to having a brand and packaging, will serve to complement treatments against diseases such as Parkinson’s, Alzheimer’s, epilepsy, fibromyalgia, among others.

Published

on

Misiones Public Health has just received the first consignment of the medical oil called MISCBD, by Misiones Cannabidiol (CBD). It is designed for the control of seizures in patients with epileptic encephalopathy for complementary treatment for said pathologies and can be used from two years of age under medical supervision. This delivery is completed after all security requirements have been met. Now it is made available to the Ministry of Health of the province, which will be in charge of free distribution with the corresponding medical prescription.

At the end of November, cannabis Sativa was harvested from the first of the five fields that the Biofactory has to develop the production of medicinal oil from cannabidiol (CBD). “With this, the field production process is being validated,” engineer Juan Serventi highlighted. As the person in charge of the Commercial Linkage of the Biofactory, he added that with this step taken, it ended up being validated in the three environments in which the cannabis sativa plantation is carried out in the Indor laboratory, greenhouse and outdoors (in the field), aiming to generate volume in oil extraction.

Meanwhile, Biofactory carried out the symbolic delivery to the Ministry of Public Health of Misiones of the first box of MISCBD 10-millimeter drippers. In this way, medical cannabis oil is made available to the public health system for free distribution in Misiones, with the corresponding medical prescription, for the treatment of refractory epilepsy. In a formal act, they highlighted that the delivery of the product involved almost 4 years of development and research.

In this way, they detailed that the Ministry of Public Health will be in charge of the distribution, while Biofactory Misiones and Misiopharma work together in the production process.

Read more on the subject and find the latest cannabis news with the Hemp.im mobile app.

SEE ALSO  The Fintech Sector in Latin America Doubled in Three Years

The CBD oil is made available to the public system in 10-millimeter drippers

As indicated, with this delivery, one more stage is completed and progress is made with the schedule outlined so that this phytomedicine product reaches the entire province through the Primary Health Care Centers (Caps) and public hospitals.

On the eve of the delivery, were present the governor of Misiones, Oscar Herrera Ahuad, the Minister of Public Health, Oscar Alarcón, the Vice President of the House of Representatives, Hugo Passalacqua, the deputy Lucas Spinelli, the president of the Biofactory, Leonardo Morzan, the general manager of the Biofactory, Luciana Imbrogno and the president of MisioPharma, Francisco Malica.

Other purposes of the CBD oil

They explained that the product made between the Biofactory and MisioPharma -MISCBD-, in addition to having a brand and packaging, will serve to complement treatments against diseases such as Parkinson’s, Alzheimer’s, epilepsy, fibromyalgia, among others. “We have achieved, in a joint effort with the company MisioPharma, the production of medical cannabis oil. In this productive process, the Biofactory does primary production, produces the buds, the flowers, and dries them, to deliver the raw material to MisioPharma so that they can extract it in the laboratory,” said the president of the Biofactory, Leonardo Morzán.

Meanwhile, Herrera Ahuad, pointed out that Misiones is a vanguard province in terms of science and applied technology, now to medical sciences to treat diseases that cannot be controlled with traditional medication.

“For this reason, beyond the presentation and delivery to the ministry, today as well as several years when the decision was made in the province of the production of medicines, it is further enhanced and in this, I highlight the work of the Biofactory and MisioPharma; there is also the communion and balance of carrying out an extremely complex production process.”

SEE ALSO  ESG: The New Direction for the Spanish Tourism Sector

“This was done with resources from the missionaries and it comes back in a product that will be beneficial; we give this initial kick in a team that has a very high potential,” he concluded. 

__

(Featured image by CBD-Infos-com via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elterritor, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Helene Lindbergh is a published author with books about entrepreneurship and investing for dummies. An advocate for financial literacy, she is also a sought-after keynote speaker for female empowerment. Her special focus is on small, independent businesses who eventually achieve financial independence. Helene is currently working on two projects—a bio compilation of women braving the world of banking, finance, crypto, tech, and AI, as well as a paper on gendered contributions in the rapidly growing healthcare market, specifically medicinal cannabis.